Clinical trial
A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care Versus Standard of Care Alone in Patients With Overt Hepatic Encephalopathy
NCT06987968 is registered in ClinicalTrials.gov with Genfit as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Controlled, Open-Label, Adaptive Dose Design, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Two Different Dwell Times of VS-01 on Top of Standard of Care Versus Standard of Care Alone in Patients With Overt Hepatic Encephalopathy
- Lead sponsor
- Genfit
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- August 25, 2025
- Completion date
- September 15, 2025
- Enrollment
- 3 (actual)
- Sites
- 6
Conditions
As the registry lists them; a condition with its own page is linked.
acute on chronic liver failure (aclf), decompensated cirrhosis, hepatic encephalopathy